0
Your Cart
Item(s)
Qty
Price

No items in your cart

 
Subtotal
$0.00
Checkout

Popular languages in United States

  • English
  • Español

Other languages

Effect of Intravaginal Dehydroepiandrosterone (DHEA) on Vaginal Atrophy
05/27/2025

This clinical trial tested whether inserting DHEA (a hormone your body naturally makes) into the vagina could restore vaginal health in postmenopausal women — without raising hormone levels in the rest of the body.

Who was involved:

  • 218 postmenopausal women with moderate-to-severe vaginal atrophy participated.
  • Researchers at medical centers in Canada led the trial.
  • The women were randomly assigned to receive either a placebo or a vaginal DHEA suppository (3.25 mg or 6.5 mg daily) for 12 weeks.

What they tested:
Researchers looked at:

  • Cell samples from the vaginal wall (to assess tissue health and thickness)
  • Vaginal pH (a higher pH is linked to infection and dryness)
  • Reported symptoms like dryness, pain during sex, irritation, and discharge
  • Blood hormone levels to make sure DHEA wasn’t leaking systemically

What they found:

  • DHEA significantly improved tissue structure, restoring normal vaginal cell layers and decreasing pH to healthier levels.
  • Women reported less pain, more moisture, and better comfort during intimacy.
  • Crucially, blood levels of estrogen and testosterone stayed the same, suggesting local benefits without systemic hormone exposure.

Why it matters:
For women who can’t or don’t want to use estrogen, intravaginal DHEA is a game-changer. It rebuilds tissue and function — locally — with minimal risk. This study helped pave the way for the now-approved product Intrarosa(prasterone).

Link: PubMed Abstract